Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.36 |
| ▸ | HINT1 | P49773 | 8/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6316021 | 0.92 | TYMP (0.39) | TYMPHPGDTAAR1HINT1KDM4E | |
| SCHEMBL6231468 | 0.92 | TAAR1 (0.37) | TYMPHPGDTAAR1HINT1KDM4E | |
| SCHEMBL6731355 | 0.90 | TYMP (0.36) | TYMPHPGDTAAR1HINT1KDM4E | |
| SCHEMBL15302162 | 0.87 | TYMP (0.44) | TYMPHPGDTAAR1HINT1KDM4E | |
| SCHEMBL16131333 | 0.87 | TYMP (0.44) | TYMPHPGDTAAR1HINT1KDM4E | |
| SCHEMBL17222397 | 0.83 | KDM4E (0.47) | TYMPTAAR1KDM4ETAS1R3TAS1R1 | |
| SCHEMBL5403467 | 0.83 | TRDMT1 (0.35) | TYMP | |
| SCHEMBL2108084 | 0.82 | HPGD (0.38) | TYMPHPGDTAAR1HINT1XDH | |
| SCHEMBL6835146 | 0.82 | TYMP (0.45) | TYMPHPGDTAAR1HINT1POLB | |
| SCHEMBL6574062 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3296306-B1 | BASE-PROTECTED OLIGONUCLEOTIDE | AJINOMOTO KK (JP) | 2022-11-09 | — | — | EP | disclosed |
| EP-2816053-B1 | BASE-PROTECTED OLIGONUCLEOTIDE | AJINOMOTO KK (JP) | 2021-03-24 | — | — | EP | disclosed |
| EP-2816053-A1 | BASE-PROTECTED OLIGONUCLEOTIDE | Ajinomoto Co., Inc. (JP) | 2014-12-24 | — | — | EP | disclosed |
| US-7273933-B1 | Methods for synthesis of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-6858722-B2 | Oligomer phosphoramidite compositions and processes for synthesizing the same | ISIS PHARMACEUTICALS, INC. (US) | 2005-02-22 | — | — | US | disclosed |
| US-6846922-B1 | Reacting phosphoramidite with hydroxyl group of nucleoside or oligonucleotide linked to solid support in presence of activating reagent comprising at least one pyridinium salt and at least one substituted imidazole | ISIS PHARMACEUTICALS, INC. (US) | 2005-01-25 | — | — | US | disclosed |
| US-20040185491-A1 | Methods for synthesis of oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | disclosed |
| EP-0983233-B1 | REAGENT USEFUL FOR SYNTHESIZING SULFURIZED OLIGONUCLEOTIDE ANALOGS | ISIS PHARMACEUTICALS INC (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20030229220-A1 | Oligomer phosphoramidite compositions and processes for synthesizing the same | RAVIKUMAR VASULINGA T (US) | 2003-12-11 | — | — | US | disclosed |
| US-6642373-B2 | Phosphitylating using pyridinium salt activators; forming phosphorate or phosphorothioate intersugar linkages | ISIS PHARMACEUTICALS, INC. | 2003-11-04 | — | — | US | disclosed |
| US-20030191304-A1 | Activators for oligonucleotide synthesis | IONIS PHARMACEUTICALS, INC. | 2003-10-09 | — | — | US | disclosed |
| US-6610842-B1 | Removing hydroxyl protecting group from compound of given formula and treating with another compound; wide range of diagnostic and therapeutic uses | ISIS PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | disclosed |
| US-6399831-B1 | THIODICARBONIC ACID DIESTER POLYSULFIDE | ISIS PHARMACEUTICALS, INC. | 2002-06-04 | — | — | US | disclosed |
| US-6274725-B1 | PROVIDING COMPOUND HAVING A HYDROXYL GROUP; REACTING WITH PHOSPHITYLATING REAGENT IN THE PRESENCE OF A PYRIDINUM SALT IN A SOLVENT UNDER CONDITIONS OF TIME, TEMPERATURE AND PRESSURE TO YIELD PHOSPHITYLATED COMPOUND | ISIS PHARMACEUTICALS, INC. | 2001-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040185491-A1 | Methods for synthesis of oligonucleotides | RNGTT, POLL, TYMP | TYMP 3/4885HPGD 4758/4885TAAR1 2030/4885 |
| US-20030229220-A1 | Oligomer phosphoramidite compositions and processes for synthesizing the same | PHOSPHO1, OSGEP, DTYMK | TYMP 10/4885HPGD 2215/4885TAAR1 4270/4885 |
| US-20030191304-A1 | Activators for oligonucleotide synthesis | ITPA, NUDT1, TYMP | TYMP 3/4885HPGD 3900/4885TAAR1 4433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.